Amorphical Ltd.

www.amorphical.com ; amorphicure.co.il

High-Tech Company

TECH VERTICALS

FoodTech, Health, Healthtech, In-Space, Life Sciences, MedTech, Pharmaceuticals, Space Operations, SpaceTech, Therapeutics, Wellness

General Data

Sector	Biomed
Company Stage:	Initial Revenues
Established	2004
Number of Employees	20
Reg. Number:	abCDe

DESCRIPTION

Amorphical is a biotechnology company advancing a new class of nano-amorphous mineral pharmacologic agents. Leveraging a proprietary, nature-inspired platform, Amorphical aims to address unmet needs in areas like pancreatic cancer, inflammatory diseases and metabolic disorders by enhancing bioavailability and optimizing pH balance at the cellular level. Supported by nearly 200 patents, extensive real-world exposure, and a GMP-certified manufacturing infrastructure, Amorphical is committed to bringing scientifically validated, disease-modifying mineral therapies to patients.

TECHNOLOGY

Inspired by the natural ability of the Australian Blue Crayfish to efficiently mobilize its calcium stores in order to shed and regrow its entire exoskeleton in only three days, Amorphical scientists have shown ACC’s safety and efficacy in preclinical studies. Moreover, the company has demonstrated ACC's high bioavailability (twice that of conventional crystalline calcium carbonate, CCC) in a double-blind, randomized, crossover study in post-menopausal women.

Pre-clinical and clinical studies conducted by Amorphical indicate that Amorphous Calcium Carbonate (ACC) has a much higher absorption rate. Based on these studies, Amorphical is collaborating with a leading international food concern to test the absorption of ACC-enriched dairy products.

Amorphical’s first product, DENSITY, is a ground-breaking calcium supplement based on the company’s innovative ACC technology. DENSITY is the most unique calcium supplement in the world and, due to the exceptionally small size of the amorphous calcium carbonate particles, the calcium ion absorption of DENSITYTM is twice as high as the most popular calcium supplements currently available today.

Products and Phases

Product	Phase
Amorphical Hypoparathyroidism ACC Capsules / AMOR 18 Powder & Inhalation	Phase II
Amorphical’s ACC clinical development program for Hypoparathyroidism includes a completed phase I study conducted at Rambam Medical Center in Israel. The preliminary results indicated that ACC was generally well tolerated and led to normalized calcium blood and urine levels after reducing the calcium dose by half for all subjects.
DENSITY	Approved
DENSITY, Amorphical's first ACC-based product, is a food supplement which has been approved for over-the-counter sale and distribution by both Israel's Ministry of Health and Hong Kong’s Centre of Food Safety. Thousands of people now use DENSITY as an everyday calcium supplement.

	TARGET MARKETS
	Pharmaceutical Companies.

	BUSINESS MODEL
	B2B

REMARKS

Date	Remark
06/10/2021	Amorphical has filed 123 patent applications: 55 patents were already allowed in different countries and 68 are in various examination stages registration process, worldwide.

CONTACT INFO

Expand / Collapse All

Main Address: Ness Ziona, Israel

Address	11 Haharash St.
City	Ness Ziona
Country	Israel
Zip	7403118

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Mr. Eden Ben	CEO
Mr. Nir Nobel	COO
Dr. Yigal Blum	CTO
Mr. Eliezer Safiev	VP, Quality Assurance
Dr. Yafit Stark	VP, Clinical & Regulation	Teva (VP, Chief Clinical Officer, Head of Oncology & Emerging Therapeutics)
Mr. Yossi Ben	Co-Founder
Mr. Amatzia Ben-Artzi	Co-Founder
Dr. Amir Berman	Co-Founder
Prof. Amir Sagi	Co-Founder
Mr. Assaf Shechter	Co-Founder

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Chairman	CEO & Co-Founder, Amorphical
abC Defghij	Board Member	Partner, Lahav Fund
abC Defghij	Board Member	N\A
abC Defghij	Board Member	N\A
abC Defghij	Board Member	Co-Founder, Cronos Israel
abC Defghij	Board Member	CFO, Maya Ofakim group

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

Sixth Round

Dec. 09, 2020

Initial Revenues

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Private Equity Fund	abCDe
abC Defghij	Holding Company	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Traditional Industry	abCDe	In addition to its investment, the Taiwanese company signed an agreement to purchase $17.5m of Amorphical products and market them in Taiwan.
abC Defghij	Other	abCDe
abC Defghij	Other	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe

Fifth Round

Mar. 17, 2020

Initial Revenues

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Private Equity Fund	abCDe
abC Defghij	Holding Company	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Other	abCDe
abC Defghij	Other	abCDe
abC Defghij	Private Investor	abCDe

Fourth Round

Mar. 10, 2016

Initial Revenues

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Private Equity Fund	abCDe
abC Defghij	Holding Company	abCDe
abC Defghij	Investment Company	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Other	abCDe
abC Defghij	Other	abCDe
abC Defghij	Private Investor	abCDe

Third Round

Jun. 11, 2013

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Private Equity Fund	abCDe
abC Defghij	Holding Company	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Other	abCDe
abC Defghij	Other	abCDe
abC Defghij	Private Investor	abCDe

Second Round

Jun. 01, 2010

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Private Equity Fund	abCDe
abC Defghij	Holding Company	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Other	abCDe
abC Defghij	Other	abCDe
abC Defghij	Private Investor	abCDe

First Round

Jun. 01, 2007

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Private Equity Fund	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Other	abCDe
abC Defghij	Other	abCDe
abC Defghij	Private Investor	abCDe

Seed

Oct. 01, 2004

Seed

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Holding Company	abCDe
abC Defghij	Technology Transfer Company	abCDe	BGN received equity in the company in exchange for providing technology & IP.
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe

	R&D Grants

Expand / Collapse All

Round

Date

Stage

Amount

Remarks

R&D Grant

Jun. 01, 2019

Initial Revenues

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

R&D Grant

Jun. 01, 2018

Initial Revenues

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij*	Government Agency	abCDe

R&D Grant

Jun. 01, 2005

R&D

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

Last Updated:	abCDe
IVC Number:	abCDe